ASH 2022 | Impact of obesity on outcomes in patients with primary ITP

Irina Murakhovskaya • 12 Dec 2022

ASH 2022

Irina Murakhovskaya, MD, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, NY, discusses the findings of a study investigating the effect of obesity on the outcomes of patients with primary immune thrombocytopenia (ITP). The study revealed that obese patients had lower platelet levels at diagnosis, were more likely to require therapy and needed more lines of treatment, and had worse overall outcomes in comparison to non-obese patients. These results suggest that addressing obesity could be beneficial for those patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Incyte: Research Funding; Alexion: Research Funding; Annexon: Research Funding; Kezar: Research Funding; Rigel: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.